Liposome-Assisted Drug Delivery in the Treatment of Multiple Sclerosis

被引:1
|
作者
Greco, Giuliana [1 ,2 ]
Sarpietro, Maria Grazia [2 ,3 ]
机构
[1] Univ Catania, Dept Biomed & Biotechnol Sci, I-95123 Catania, Italy
[2] Univ Catania, NANOMED Res Ctr Nanomed & Pharmaceut Nanotechnol, I-95125 Catania, Italy
[3] Univ Catania, Dept Drug & Hlth Sci, I-95125 Catania, Italy
来源
MOLECULES | 2024年 / 29卷 / 19期
关键词
multiple sclerosis; BBB; EAE models; nanocarriers; liposomes; drug delivery; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; GUINEA-PIGS; FATTY-ACID; T-CELLS; MYELIN; SUPPRESSION; PATHOGENESIS; INFLAMMATION; ANTIBODIES; PEPTIDE;
D O I
10.3390/molecules29194689
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Multiple sclerosis (MS) is an immune-mediated demyelinating disease of the nervous system that leads to neurological dysfunctions and severe disabilities. It is worth noting that conventional pharmacotherapy is poorly selective and causes toxicity problems and several systemic side effects. Thus, there is a need to develop new approaches to this medical challenge. The use of nanocarriers for drug delivery represents a good strategy to overcome several issues such as high therapeutic drug doses with side effects, such as diarrhea, nausea, and abdominal pain, and drug degradation processes; in addition, nanocarriers can provide controlled and targeted drug release. This review describes the application of liposomes for the delivery of pharmaceutical actives to target MS. Firstly, MS is explained. Then, liposomes are described along with their preparation, characterization, and stability. The literature about the use of liposomes for the treatment of MS is then analyzed.
引用
收藏
页数:22
相关论文
共 50 条
  • [21] Cationic liposome mediated drug delivery
    Campbell, RB
    Straubinger, RM
    BIOPHYSICAL JOURNAL, 1997, 72 (02) : WP313 - WP313
  • [22] Drug Insight: interferon treatment in multiple sclerosis
    Marrie, RA
    Rudick, RA
    NATURE CLINICAL PRACTICE NEUROLOGY, 2006, 2 (01): : 34 - 44
  • [23] Multiple sclerosis: pharmacogenomics and personalised drug treatment
    Annibali, V.
    Ristori, G.
    Cannoni, S.
    Romano, S.
    Visconti, A.
    Ghazaryan, A.
    Talamanca, L. Figa
    Salvetti, M.
    Mechelli, R.
    NEUROLOGICAL SCIENCES, 2006, 27 (Suppl 5) : S347 - S349
  • [24] Multiple sclerosis: pharmacogenomics and personalised drug treatment
    V. Annibali
    G. Ristori
    S. Cannoni
    S. Romano
    A. Visconti
    A. Ghazaryan
    L. Figà Talamanca
    M. Salvetti
    R. Mechelli
    Neurological Sciences, 2006, 27 : s347 - s349
  • [25] Multiple sclerosis: Therapeutic applications of advancing drug delivery systems
    Dolati, Sanam
    Babaloo, Zohreh
    Jadidi-Niaragh, Farhad
    Ayromlou, Hormoz
    Sadreddini, Sanam
    Yousefi, Mehdi
    BIOMEDICINE & PHARMACOTHERAPY, 2017, 86 : 343 - 353
  • [26] Antioxidant Therapies in the Treatment of Multiple Sclerosis
    Jimenez-Jimenez, Felix Javier
    Alonso-Navarro, Hortensia
    Salgado-Camara, Paula
    Garcia-Martin, Elena
    Agundez, Jose A. G.
    BIOMOLECULES, 2024, 14 (10)
  • [27] Liposome-Hydrogel Composites for Controlled Drug Delivery Applications
    Binaymotlagh, Roya
    Haghighi, Farid Hajareh
    Chronopoulou, Laura
    Palocci, Cleofe
    GELS, 2024, 10 (04)
  • [28] Targeting Fibronectin to Overcome Remyelination Failure in Multiple Sclerosis: The Need for Brain- and Lesion-Targeted Drug Delivery
    van Schaik, Pauline E. M.
    Zuhorn, Inge S.
    Baron, Wia
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (15)
  • [29] Liposome based drug delivery as a potential treatment option for Alzheimer's disease
    Hernandez, Carely
    Shukla, Surabhi
    NEURAL REGENERATION RESEARCH, 2022, 17 (06) : 1190 - 1198
  • [30] TREATMENT OF MULTIPLE SCLEROSIS
    Bosnjak-Pasic, Marija
    Vidrih, Branka
    Miskov, Snjezana
    Demarin, Vida
    ACTA CLINICA CROATICA, 2009, 48 (03) : 349 - 353